WELLNEX

ASX/AIM Announcement

31 July 2026

Quarterly Update and Appendix 4C — June 2026

HIGHLIGHTS

- Second consecutive quarter of positive net operating cash flow
- H2 FY26 operating cash flow of approximately $0.5 million, a turnaround of approximately $3.6 million (H1 FY26: outflow of $3.1 million).
- Customer receipts of $5.7 million for the quarter and $22.0 million for FY26; H2 FY26 up 28% on H1 FY26
- Cash at 30 June 2026 of $862k, up from $217k at 31 March 2026
- Continued cost discipline, with staff costs down 21% quarter-on-quarter

Wellnex Life Limited (ASX/AIM: WNX) ("Wellnex" or "the Company") is pleased to report a second consecutive quarter of positive net operating cash flow, confirming the turnaround momentum and the effectiveness of the Company's focus on revenue quality and cost discipline.

Receipts from customers were $5.7 million for the quarter, taking total receipts for FY26 to $22.0 million. Receipts for the second half of FY26 of $12.4 million were 28% higher than the first half. Receipts for the quarter of $5.7 million included approximately $2.4 million from the Company's licensing partnership with Haleon, alongside continued strong receipts from the Company's major retail and pharmacy channel partners including Coles, Woolworths, Chemist Warehouse and the major pharmacy wholesalers.

Net operating cash flow for the quarter was positive at $63k (Q3 FY26: $412k positive). Operating cash flow for the second half of FY26 was approximately $0.5 million positive, compared with an outflow of $3.1 million in the first half, a turnaround of approximately $3.6 million half-on-half. This improvement was driven by higher receipts and disciplined cost management, with staff costs reducing 21% quarter-on-quarter to $588k and advertising and marketing spend held at $518k.

Revenue

Revenue	Q4 FY26	Q3 FY26	% Change
Brands	$4.4 million	$3.5 million	25.7%
IP Licensing	$2.6 million	$1.6 million	62.5%
Total	**$7.0 million**	**$5.1 million**	**37.3%**
Gross Profit	$2.0 million	$1.5 million	33.3%

Wellnex Life Limited
Building 2, Level 3, Suite 72, 574 Plummer Street
Port Melbourne VIC Australia
info@wellnexlife.com.au Phone: +61 3 8399 9419

WELLNEX

Cash Position and Funding

The Company closed the quarter with cash and cash equivalents of $862k, up from $217k at 31 March 2026.

The Company's financing facilities comprise a secured revolving trade and debtor facility with Scottish Pacific and a secured loan facility with Reach Wholesale, details of which are set out in section 7 of the accompanying Appendix 4C.

Payments to Related Parties

Payments to related parties and their associates during the quarter, as set out in item 6.1 of the Appendix 4C, totalled $296k. These payments comprised directors' fees, executive remuneration and associated superannuation paid to directors and director-related entities in the ordinary course of business. The repayment date for the loans from former directors has been extended to end of August 2026 at no additional cost to the Company.

Outlook

Wellnex enters FY27 with positive operating cash flow momentum, an improving cash position and an established platform across branded consumer health products and IP licensing. The Company remains focused on building on the second-half turnaround through continued revenue growth with its major retail, pharmacy and licensing partners, and on maintaining the cost discipline delivered through FY26. As previously announced, the Company continues to assess opportunities to strengthen the balance sheet.

This ASX/AIM announcement has been authorised by the Board of Wellnex Life Limited (ASX/AIM:WNX).

The information contained within this announcement is deemed by the Company to constitute inside information pursuant to article 7 of EU Regulation 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 as amended.

--- END ---

For further information, please contact:

Wellnex Life Limited (ASX/AIM:WNX)

Eric Jiang

Interim Executive Chairman

E: eric.j@wellnexlife.com.au

WELLNEX

UK Investors

Strand Hanson (Financial & Nominated Advisor)

James Harris / Richard Johnson	Tel: +44 (0) 20 7409 3494
Orana Corporate LLP (Joint Broker)	swykeham@oranacorp.com
Sebastian Wykeham	
S.P. Angel Corporate Finance LLP (Joint Broker)	Tel: +44 (0)20 3470 0470
David Hignell / Vadim Alexandre	

To learn more, please visit: https://wellnexlife.com.au/

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity
WELLNEX LIFE LIMITED

ABN	Quarter ended ("current quarter")
77 150 759 363	30 June 2026

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	5,687	21,995
1.2	Payments for		
	(a) research and development	(26)	(320)
	(b) product manufacturing and operating costs	(3,474)	(14,170)
	(c) advertising and marketing	(518)	(2,485)
	(d) leased assets		
	(e) staff costs	(588)	(3,277)
	(f) administration and corporate costs	(536)	(2,336)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	0	0
1.5	Interest and other costs of finance paid	(274)	(1,055)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (GST refund/(paid))	(209)	(1,020)
1.9	**Net cash from / (used in) operating activities**	**63**	**(2,667)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses		
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	
	(f) other non-current assets	-	-

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (12 months) $A'000**
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	10	10
	(f) other non-current assets	-	-
2.3	Loan repayment from other entity	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (cash acquired from CBDG Administration)	-	
2.6	**Net cash from / (used in) investing activities**	**10**	**10**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(40)	(1,168)
3.5	Proceeds from borrowings	3,497	18,468
3.6	Repayment of borrowings	(2,884)	(14,102)
3.7	Transaction costs related to loans and borrowings	-	(176)
3.8	Share applications to be refunded	-	-
3.9	Other (repayment of lease liabilities)	-	-
3.10	**Net cash from / (used in) financing activities**	**572**	**3,022**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	217	497
4.2	Net cash from / (used in) operating activities (item 1.9 above)	63	(2,667)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	10	10

Consolidated statement of cash flows		Current quarter $A'000	Year to date (12 months) $A'000
4.4	Net cash from / (used in) financing activities (item 3.10 above)	572	3,022
4.5	Effect of movement in exchange rates on cash held	-	(1)
4.6	**Cash and cash equivalents at end of period**	**862**	**862**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	862	217
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (funds held in trust)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**862**	**217**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	296
6.2	Aggregate amount of payments to related parties and their associates included in item 2	

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	9,195	(6,716)
7.2	Credit standby arrangements	-	-
7.3	Other (Director's loan)	2,675	(2,675)
7.4	**Total financing facilities**	**11,870**	**(9,391)**
7.5	**Unused financing facilities available at quarter end**		2,479

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

1. Secured Revolving Trade and Debtor Facility with Scottish Pacific of $3.8 million

Interest Rate: BBSY plus 6.8%.

2. Secured loan facility with Reach Wholesale of up to $5.325 million at 14% per annum expiring August 2027. The amount shown in Section 7 is for the full amount drawn down ($5.325 million) at the close of the period

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	63
8.2	Cash and cash equivalents at quarter end (item 4.6)	862
8.3	Unused finance facilities available at quarter end (item 7.5)	2,479
8.4	Total available funding (item 8.2 + item 8.3)	3,341
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	N/A

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

31 July 2026

Date: ....

The Board of Directors

Authorised by: ....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.